Lithium Prices Surge as 2025 Market Recovery Gains Serious Momentum
As lithium prices continue to improve, two companies in the sector could benefit from stronger sentiment. Both have projects that are sensitive to shifts in pricing, and a firmer market often brings renewed attention to companies with established footholds in the lithium space. With confidence returning strongly to the sector, these types of stocks tend to attract more interest from investors watching for signs of a broader recovery.
Atlas Lithium Corp.
Atlas Lithium Corp. (ATLX:NASDAQ) recently secured approximately US$10 million in gross proceeds through a registered direct offering with two U.S.-based institutional investors. Atlas Lithium stated that proceeds would support the advancement of the Neves Lithium Project in Brazil and general corporate purposes. Chairman and CEO Marc Fogassa said, “We are honored to add as our newest shareholders these two premier, fundamental institutional investors. We believe that their investment strengthens our corporate profile as well as our balance sheet.”
In a November 17 research note, Heiko Ihle of H.C. Wainwright and Co. highlighted extensive industry engagement in the development process for the Neves project. Ihle stated that four technical site visits in September attracted between 11 and 17 contractors per event and generated more than 2,800 clarification questions from prospective bidders. He wrote that “the competitive bidding process supports disciplined cost outcomes and validates the project’s attractiveness,” noting that procurement packages tied to electromechanical assembly, mine operations, and internal road engineering accounted for approximately 70% of estimated capital expenditures.
Ihle also referenced the company’s August definitive feasibility study, which he said demonstrated strong economics. He wrote, “We remain pleased with the contents and financial projections of Atlas’ definitive feasibility study,” citing a US$539 million after-tax net present value, a 145% internal rate of return, and an 11-month payback period. The study projected operating costs of US$489 per ton and attributed the cost structure in part to low impurity, near-surface spodumene, and a fully paid-for dense media separation plant already in Brazil. Ihle added that the combination positioned the project competitively within the lithium development landscape. [OWNERSHIP_CHART-11040]
In a November 24 update, Ihle reaffirmed a Buy rating for Atlas Lithium and assigned a 12-month price target of US$12 per share. He noted that the revised target, though lower than a prior estimate, still implied a return of approximately 175% based on the offering price. Ihle incorporated the company’s 28.15% interest in Atlas Critical Minerals Corp. into his valuation and wrote that Atlas Lithium’s broader portfolio contributed to long-term optionality beyond the Neves project alone.
Ihle also commented on the company’s exploration progress at its Salinas project, located roughly 60 miles north of Neves. He stated that initial drilling confirmed spodumene-rich mineralization near surface and described the area as “a key area of future growth that is mostly ignored by the market thus far.” According to his note, Salinas represented an additional source of resource expansion potential and complemented the company’s existing land position within Brazil’s Lithium Valley.
Financial results also formed part of Ihle’s analysis. He reported that Atlas Lithium recorded a third-quarter 2025 net loss of US$8 million, or US$0.35 per share, compared with a US$9.7 million net loss in the same period of 2024. Ihle wrote, “We view current financials as largely immaterial given the transitional nature of the firm,” noting that Atlas Lithium was in the development phase and had begun to receive regulatory and operational approvals needed to advance construction.
One of the most significant developments cited by Ihle was the company’s receipt of a Portaria de Lavra from Brazil’s Ministry of Mines and Energy. This mining concession granted Atlas Lithium full mineral title and the right to begin and maintain mining operations at Neves. Ihle wrote, “We now anticipate near-term production… which may prove to be a major catalyst,” and concluded that Atlas Lithium’s “low cost status remains a key theme of anticipated operations.”
Atlas Lithium reported in its investor presentation that the Neves project carried a projected operating cost of US$489 per ton of lithium concentrate, supported by open-pit mining and a fully paid US$30 million dense media separation plant already delivered to Brazil. The company stated that Neves had an estimated after-tax net present value of US$539 million and an 11-month payback period based on the assumptions outlined in its definitive feasibility study. Over its initial 6.5-year mine life, Neves was expected to produce approximately 950,000 tonnes of spodumene concentrate grading 5.5% lithium oxide.
The company holds 557 square kilometers of mineral rights in Brazil’s Lithium Valley, which it reports is the largest exploration footprint in the region. Expansion opportunities include the 100% owned Salinas Project and targets adjacent to existing or recently acquired lithium operations. In addition to its lithium assets, Atlas Lithium maintains a 28% interest in Atlas Critical Minerals, which has exposure to rare earths, graphite, titanium, and uranium projects in Brazil. The company has also executed offtake and equity agreements with Mitsui, Chengxin, and Yahua, each of which committed to acquiring lithium concentrate or equity interests aligned with the Neves development timeline.
1As for ownership and share structure, management owns approximately 24% of Atlas Lithium common shares. Strategic partner Mitsui & Co. Ltd. has 7.94%. Numerous institutions hold ~11%. Retail investors own the rest.
Atlas Lithium has 26.5 million shares outstanding. Its market cap is ~US$100M. Its 52-week range is US$3.54–8.32 per share.
Libra Energy Materials
Libra Energy Materials (LIBR:CSE; W0R0:FSE) is the newest dedicated lithium explorer to go public. Since its go-public in July, Libra has been quietly accumulating prospective projects across the Americas, at an opportune time when lithium projects were selling for pennies on the dollar, growing its portfolio from six projects to thirty-seven with less than 10% dilution. The company continues to advance its projects in Quebec and Brazil, while some of its Ontario assets are supported by an earn-in agreement with Bill Gates-backed AI explorer, KoBold Metals. The KoBold agreement, established in late 2024, provides a multi-year framework for exploration across the Flanders South, Flanders North, and SBC properties, three district-scale land packages within emerging lithium belts. Under the structure, KoBold may earn up to a 75% interest in each project through staged exploration expenditures that may total up to CA$33 million over six years.
The arrangement also includes a technical committee with equal representation from both companies, monthly contract payments to Libra for exploration services, and milestone payments tied to future resource and study achievements at Flanders North and Flanders South. As KoBold completes Stage 1 and Stage 2 thresholds on a project basis, ownership would transition to joint venture status, with Libra retaining exposure through a 49% or 25% stake, depending on the stage reached. The agreement remains the foundation for ongoing exploration planning and property maintenance for these three projects.
The three Ontario properties covered by the agreement host a broad inventory of pegmatite targets identified through early groundwork. At Flanders North, LIDAR and prospecting work in 2023 identified hundreds of LCT-type pegmatites, some up to 200 meters wide. At Flanders South, early sampling confirmed spodumene mineralization at the Homer pegmatite with grades up to 2.86% Li₂O, alongside the Nelson tantalite-bearing pegmatite, which returned assays up to 4,469 ppm Ta₂O₅. Together, the properties cover more than 40,000 hectares across the Quetico Subprovince with access via logging roads and the all-season Flanders Road. [OWNERSHIP_CHART-11492]
The SBC project, also governed under the KoBold agreement, covers more than 15,000 hectares south of Pickle Lake and features one of the newest spodumene discoveries in Ontario. Libra’s 2024 reconnaissance work identified 18 spodumene-bearing outcrops over a 12-kilometer trend, including individual pegmatites up to 30 meters wide and grab samples grading up to 6.64% Li₂O. Only a small percentage of the property has been explored to date, and the discovery earned Libra the 2024 Bernie Schnieders Discovery of the Year Award.
Beyond the earn-in properties, Libra is progressing additional projects in Canada, including Toivo, Nemiscau, Wegucci, and Stimson. Meanwhile in Brazil, the company continues to explore across twenty-one lithium projects, eight graphite projects, and one cobalt-nickel project. These properties were selected based on regional geological trends, historical drill indications, and the presence of wide pegmatite outcrops documented through mapping and government surveys. Current plans focus on LiDAR surveys, prospecting, and reconnaissance mapping to confirm spodumene mineralization ahead of potential drilling programs. This tiered project pipeline positions Libra for continued, year-round field activity and regional targeting across several prolific lithium belts.
Management and the company’s top shareholders have also entered into an internal lockup agreement, providing additional alignment and limiting share movement during key stages of Libra’s exploration and development work.
134.10% of Libra is held by management and insiders. Of them, David Goodman, Chairman, holds the most at 14.05%. Strategic entities hold 3.76%. The rest is retail.
Libra has 67.27 million shares outstanding, with a market cap of approximately CA$10 million.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Source: https://www.streetwisereports.com/article/2025/12/16/lithium-prices-surge-as-2025-market-recovery-gains-serious-momentum.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

